



MUCOSAL IMMUNOLOGY DAYS

July 8-10, 2027

Symposium 248
GOTHENBURG, SWEDEN



Preface 4

Scientific Program 6

List of Speakers, Moderators and Scientific Organizers 12

Posters 15

Information 16



An application has been made to the UEMS EACCME® for CME accreditation of this event. The number of credits awarded will be printed in the final program.

PREFACE

Building on the success of the previous translational meetings on inflammatory bowel disease (IBD) in Potsdam and Oxford, the 2027 Falk Symposium in Gothenburg continues the dialogue between basic and clinical research by focusing on the biological and clinical continuum of IBD development. The meeting will provide a unique forum for clinical scientists, basic scientists and translational researchers to discuss how advances in fundamental immunology, microbiology, genetics and systems medicine can translate into improved patient care, and how clinical observations can, in turn, drive new scientific discoveries.

Rather than viewing IBD as a static disease, this symposium follows its natural history from health to disease and beyond. We begin by exploring the mechanisms that maintain intestinal homeostasis. From there, we examine the earliest phases of disease development, discussing the transition from health to immune dysregulation, the border of autoimmune disease, and the progression from preclinical immune activation to target organ involvement. Particular emphasis will be placed on the biological events that precede symptom onset and on identifying opportunities for early intervention.

We then follow the patient journey into established clinical disease, addressing the challenges of diagnosis, disease stratification, disease modification and emerging opportunities in precision medicine. As our understanding of disease heterogeneity evolves, integrating molecular mechanisms with clinical phenotypes becomes increasingly important for personalized therapy.

Beyond disease control, the symposium addresses the long-term consequences of IBD, including disease progression, structural complications, disability and the challenges of ageing with IBD. Understanding these later stages of disease is essential for improving lifelong health and quality of life in an expanding population of patients

Finally, we look ahead to the next generation of innovation in the field. Emerging technologies, multi-omics, artificial intelligence, biomarker discovery and preventive strategies are opening new perspectives for disease interception before irreversible tissue damage occurs - having the potential to fundamentally reshape IBD management

A hallmark of this symposium is its commitment to fostering dialogue across disciplines and career stages. By bringing together experts from complementary fields and encouraging active discussion, we aim to strengthen the translational bridge between mechanistic research and clinical application. The program also highlights the contributions of the next generation of investigators through dedicated poster pitch sessions.

We hope that this symposium will stimulate scientific exchange, inspire new collaborations and accelerate the translation of innovative discoveries into meaningful advances for people living with IBD.

Petter Brodin, Charlotte Hedin, Jonas Halfvarson, Britta Siegmund

MUCOSAL IMMUNOLOGY DAYS

July 8-10, 2027

Scientific Organization:

Petter Brodin, Stockholm
Jonas Halfvarson, Örebro
Charlotte Hedin, Stockholm
Britta Siegmund, Berlin

Congress Venue:

Radisson Blu Scandinavia
Södra Hamngatan 59
401 24 Gothenburg
Sweden

For admission to scientific events your name badge should be clearly visible.

Accompanying persons are not permitted during the conference at any time.

Call for Posters:

An ePoster session will be held.
For details see page 15.

Start of Registration:

Thursday, July 8, 2027
12:30 h at the congress office

Publication Date of the Final

Program:

July 2027

The final program will be available on the website www.falkfoundation.org one week before the start of the symposium.

THURSDAY, JULY 8, 2027

13:00 Networking Lunch

14:00 Welcome

SESSION I

Healthy gut: Foundations of long-term intestinal health

Chairs

14:05 Keynote lecture: Establishing immune-microbiome interactions in newborns
Petter Brodin, Stockholm

14:35 Intestinal mucus: The protective layer?
Malin Johansson, Gothenburg

14:50 Intestinal T cell immunity: A defence mechanism?
Marianne Quiding-Järbrink, Gothenburg

15:05 Dendritic cells as regulators of intestinal immune homeostasis
William Agace, Copenhagen

15:20 **Panel discussion**
*William Agace, Copenhagen; Petter Brodin, Stockholm;
Malin Johansson, Gothenburg; Marianne Quiding-Järbrink,
Gothenburg and Chairs*

15:50 Coffee break with ePoster session

SESSION II

Border of autoimmune disease: Early disease initiation

Chairs

- 16:40** Antibody patterns reflecting previous microbial exposure
Arno Bourgonje, Groningen
-
- 16:55** Early proteomic signals in IBD and the role of $\alpha\beta6$
Olle Grännö, Örebro
-
- 17:10** Environmental exposure: A driver of early disease?
Manasi Agrawal, New York
-
- 17:25** **Panel discussion**
Manasi Agrawal, New York; Arno Bourgonje, Groningen; Olle Grännö, Örebro and Chairs

SESSION III

Poster pitches

Chairs

- 17:50** 10 poster pitches (each 3 minutes plus 2 minutes discussion)
-
- 18:40** **Welcome evening**

FRIDAY, JULY 9, 2027

SESSION IV

Border of autoimmune disease: Progression to target organ involvement

Chairs

- | | |
|-------|--|
| 09:00 | Keynote lecture: Experience from type 1 diabetes
<i>Cate Speake, Seattle</i> |
| 09:30 | Detecting subclinical IBD
<i>Aleksejs Sazonovs, Copenhagen</i> |
| 09:45 | Early mucosal changes
<i>Eduardo J. Villablanca, Stockholm</i> |
| 10:00 | Impact of the intestinal microbiota on disease development
<i>Fredrik Bäckhed, Gothenburg</i> |
| 10:15 | Organoids as model systems: Can early disease be mimicked?
<i>Calvin Kuo, Stanford</i> |
| 10:30 | Panel discussion
<i>Fredrik Bäckhed, Gothenburg; Calvin Kuo, Stanford; Aleksejs Sazonovs, Copenhagen; Cate Speake, Seattle; Eduardo J. Villablanca, Stockholm and Chairs</i> |
| 11:00 | Coffee break with ePoster session |

SESSION V

Clinical disease: From symptoms to diagnosis

Chairs

- | | |
|-------|--|
| 11:50 | Recognizing the four stages of IBD
<i>Gilaad G. Kaplan, Calgary</i> |
| 12:05 | Early endoscopic changes
<i>Marietta Iacucci, Cork</i> |
| 12:20 | Prognostic markers: The biology of disease progression
<i>James Lee, London</i> |

12:35 **Panel discussion**
Marietta Iacucci, Cork; Gilaad G. Kaplan, Calgary; James Lee, London and Chairs

13:00 **Lunch break with ePoster session**

SESSION VI

Disease modification: Towards precision medicine

Chairs

14:00 Keynote lecture: The role of B cells in IBD
Saurabh Mehandru, New York

14:30 B cell therapies
Raja Atreya, Erlangen

14:45 Cytokine-blocking antibodies: Cause or consequence?
Holm Uhlig, Oxford

15:00 Can genetics explain IBD in 2027?
Laura Fachal, Cambridge

15:15 **Panel discussion**
Raja Atreya, Erlangen; Laura Fachal, Cambridge; Saurabh Mehandru, New York; Holm Uhlig, Oxford and Chairs

15:45 **Coffee break with ePoster session**

SESSION VII

Poster pitches

Chairs

16:35 10 poster pitches (each 3 minutes plus 2 minutes discussion)

FRIDAY, JULY 9, 2027

SESSION VIII

Late-stage disease: Progression and complications

Chairs	
17:25	Keynote lecture: No inflammation: No fibrosis? <i>Florian Rieder, Cleveland</i>
17:55	Spatial information on fistulizing disease <i>N. N.</i>
18:10	What can we learn from complicated cases? <i>Carl Weidinger, Berlin</i>
18:25	Panel discussion <i>Florian Rieder, Cleveland; Carl Weidinger, Berlin and Chairs</i>
18:50	Presentation of Poster Awards
19:00	Scientific networking with flying buffet

SATURDAY, JULY 10, 2027

SESSION IX

Long-term health: Aging with IBD	
9:00	Aging of the glycome <i>Gordon Lauc, Zagreb</i>
9:15	Cardiovascular risk in IBD <i>Johan Burisch, Hvidovre</i>
9:30	Infection risk in IBD <i>Ola Olén, Stockholm</i>
9:45	Malignancy risk in IBD <i>Jonas F. Ludvigsson, Örebro</i>
10:00	Pregnancy and reproductive health in IBD <i>N. N.</i>
10:15	Panel discussion <i>Johan Burisch, Hvidovre; Gordon Lauc, Zagreb; Jonas F. Ludvigsson, Örebro and Chairs</i>
10:45	Coffee break with ePoster session

SESSION X

Disease interception: The future of IBD	
11:35	Screening high-risk individuals: Need for at-risk clinics? <i>Joana Torres, Lisbon</i>
11:50	Molecular understanding of preventive strategies: Appendectomy in UC <i>N. N.</i>
12:05	Prevention studies in IBD <i>N. N.</i>
12:20	Panel discussion <i>All speakers of Session X and Chairs</i>
12:45	Closing remarks
12:55	Closing discussion with lunch

LIST OF SPEAKERS, MODERATORS AND SCIENTIFIC ORGANIZERS

Prof. William Agace

Skin Immunology Research Center
University of Copenhagen
Blegdamsvej 3B
Copenhagen
Denmark

Prof. Manasi Agrawal

Departments of Medicine and
Environmental Medicine
Icahn School of Medicine at Mount Sinai
1 Gustave L. Levy Place
NY 10029 New York
United States

Prof. Dr. med. Raja Atreya

Medizinische Klinik 1
Universitätsklinikum Erlangen
Ulmenweg 18
91054 Erlangen
Germany

Prof. Fredrik Bäckhed

Department of Molecular and Clinical
Medicine
University of Gothenburg
Wallenberglab, Bruna straket 16
41345 Gothenburg
Sweden

Dr. Arno Bourgonje, PhD

Department of Gastroenterology and
Hepatology
University Medical Center Groningen
Hanzeplein 1
9713 GZ Groningen
The Netherlands

Prof. Petter Brodin

K6 Klinisk pediatrik Brodin
Karolinska University Hospital
Karolinska Universitetssjukhuset
Eugeniavägen 3
17177 Stockholm
Sweden

Prof. Johan Burisch

Gastrounit, Medical Division &
Copenhagen IBD Center
Copenhagen University Hospital -
Amager and Hvidovre
Kettegård Alle 30
2650 Hvidovre
Denmark

Dr. Laura Fachal

Wellcome Sanger Institute
Genomics of Inflammation and
Immunity – Anderson Lab
Wellcome Genome Campus
Hinxton CB10 1SA Cambridge
United Kingdom

Dr. Olle Grännö

Department of Laboratory Medicine,
Clinical Microbiology
Örebro University
Fakultetsgatan 1
70182 Örebro
Sweden

Prof. Jonas Halfvarson

School of Medical Science
Örebro University
Universitetssjukhuset Örebro (USÖ)
70182 Örebro
Sweden

Dr. Charlotte Hedin

Department of Medicine
Karolinska Institute
Eugenivägen 11 B4:09
17164 Solna
Sweden

Prof. Marietta Iacucci

College of Medicine and Health
University College Cork
3rd Floor, Erinvilla, Western Road
T12 EKDO Cork
Ireland

Prof. Malin Johansson

Department of Medical Biochemistry
and Cell Biology
University of Gothenburg
Medicinaregatan 9C
41390 Gothenburg
Sweden

Prof. Gilaad G. Kaplan

Department of Medicine
University of Calgary
3280 University Drive NW
T2N 4Z6 Calgary, Alberta
Canada

Prof. Calvin Kuo

Medicine - Hematology
Stanford University
291 Campus Drive
94305 Stanford, CA
United States

Prof. Gordan Lauc

Faculty of Pharmacy and Biochemistry
University of Zagreb
Ul. Ante Kovacica
10000 Zagreb
Croatia

Prof. James Lee

Lee Lab, Genetic Mechanisms of
Disease Laboratory
The Francis Crick Institute
1 Midland Rd
NW1 1AT London
United Kingdom

Prof. Jonas F. Ludvigsson

Karolinska Institute
Örebro University Hospital
Nobels väg 6
17177 Stockholm
Sweden

Dr. Saurabh Mehandru M.D.

Division of Gastroenterology
Icahn School of Medicine at Mount
Sinai
1425 Madison Avenue
10029 New York
United States

Prof. Ola Olén

Department of Medicine
Karolinska Institute
Maria Aspmans gata 30A
17164 Solna, Stockholm
Sweden

Prof. Marianne Guiding-Järbrink

Institute of Biomedicine
University of Gothenburg
Box 435
40530 Gothenburg
Sweden

Florian Rieder M.D.

Dept. of Gastroenterology, Hepatology
and Nutrition
The Cleveland Clinic Foundation
9500 Euclid Avenue
OH 44195 Cleveland
United States

Prof. Aleksejs Sazanovs M.D.

Center for Molecular Prediction of
Inflammatory Bowel Disease
A.C. Meyers Vænge 15
2450 Copenhagen SV
Denmark

Prof. Dr. med. Britta Siegmund

Medizinische Klinik I - Gastroenterologie/
Infektiologie/Rheumatologie
Charité – Universitätsmedizin Berlin
Hindenburgdamm 30
12203 Berlin
Germany

Dr. Cate Speake

Center for Interventional Immunology
Benaroya Research Institute at Virginia
Mason
1201 Ninth Avenue
WA 98101 Seattle
United States

Dr. Joana Torres

Gastroenterology
Hospital Beatrix Angelo & Hospital da
Luz
Rua Carlos Alberto
2674-514 Lisbon
Portugal

Prof. Holm Uhlig

John Radcliffe Hospital
Headley Way Headington
OX3 9DU Oxford
United Kingdom

Prof. Eduardo J. Villablanca Ph.D.

Division of Immunology and
Respiratory Medicine
Karolinska Institute
Nobels väg 6
171 77 Stockholm
Sweden

Prof. Dr. med. Carl Weidinger

Medizinische Klinik für Gastroenterologie,
Infektiologie und Rheumatologie
Charité, Campus Benjamin Franklin
Hindenburgdamm 30
12203 Berlin
Germany

POSTER SESSION

ePosters will be displayed on our screens on July 8-10, 2027. We kindly ask the authors to be present during coffee and lunch breaks on both days to discuss their work.

CALL FOR POSTERS

Please submit your abstract by April 4, 2027, using our online submission system (<https://poster.falkfoundation.org>). The system will guide you through the submission process and provide further information on formatting requirements.

The abstracts will be reviewed by the scientific organizers, with preference given to those that align thematically with one of the final meeting sessions. Accepted abstracts will be published in the final program.

Abstract submitters will be informed about acceptance and receive further instructions in April 2027.

For the first author of an accepted abstract, registration fee and accommodation (July 8-10, 2027) will be covered during Symposium 248. Travel expenses will not be covered.

POSTER AWARDS

Prizes of up to EUR 3.000, along with coverage of travel expenses, will be awarded for the best posters. Winners

will be invited to give a short presentation (2-5 minutes) of their poster during the award ceremony.

REGISTRATION



You can register for the event via our homepage:

www.falkfoundation.org

Registration is only possible online.

You will receive an automatic confirmation of registration by e-mail.

Please transfer the congress fee to the bank account listed in the e-mail within two weeks.

CONGRESS FEES

Scientific Program of Symposium 248	EUR 300
Students (copy of student ID required)	EUR 150

The congress fees include:

- Pre-Opening and Welcome on Thursday, July 8, 2027
- Refreshments during coffee breaks
- Lunch on Friday and Saturday, July 9 and 10, 2027
- Scientific networking with flying buffet on Friday evening, July 9, 2027
- A copy of the final program

CONGRESS OFFICE AND REGISTRATION

Opening Hours:

Thursday, July 8,	12.30 – 18:30 h
Friday, July 9,	08:00 – 19:00 h
Saturday, July 10,	08:30 – 13:00 h

The Falk Foundation will take pictures during the meeting. Additionally, parts of the meeting might be recorded. By participating all attendees consent and agree with the recording and the photo shoots.

ARRIVAL

Radisson Blu Scandinavia

Södra Hamngatan 59
401 24 Gothenborg
Sweden

By car

The hotel is located across the street from Gothenburg Central Station. Drivers can take the Ullevi exit from the E6 and follow the signs toward the city center. At the third traffic light, continue straight ahead and follow the signs toward Brunnsparcken along the canal for approximately 300 m. When the road curves to the left (immediately after a small bridge), continue straight, and the hotel will be on your left-hand side. The hotel offers safe car parking with direct access to the hotel. EV parking is available.


By plane

From Landvetter Airport it's 24 km (25 min by car). There is an airport bus which takes approx. 20 min (direction Gothenburg Nils Ericsonterminal, exit at Gothenburg Kungssportsplatsen. Walk through Östra Larmgatan, turn right onto Södra Hamngatan and you will reach the hotel, 450 m from the bus stop)

By train

The Central Station is just 200 m away.

**Registration via www.falkfoundation.org
or simply scan and register**



Together we know more. Together we do more.

Falk Foundation e.V. | Leinenweberstr. 5 | 79108 Freiburg | Germany
T: +49 761 1514-400 | F: +49 761 1514-460 | E-Mail: meeting@falkfoundation.org
www.falkfoundation.org